Evidence map›Paper›PMID 42298870›Full record

ArticleInternational journal of laboratory hematology2026

Optimization of Analytical Performances and Routine Laboratory Implementation of NPM1 Mutation Detection by Digital PCR in the Diagnosis and Monitoring of NPM1 -Mutated Acute Myeloid Leukemias.

Chloé Ferrari, Brice Coulleray, Pauline Kerneves, Carole Geara, Dina Naguib, Guénaelle Levallet, Elizabeth Battersby, Sylvain Chantepie, Yohann Repessé, Coralie Nectoux and 1 more

Abstract read
In one paragraph

Article in International journal of laboratory hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chloé FerrariCentre Hospitalier Universitaire de Caen Normandie, Caen, France.
Brice CoullerayCentre Hospitalier Universitaire de Caen Normandie, Caen, France.
Pauline KernevesCentre Hospitalier Universitaire de Caen Normandie, Caen, France.
Carole GearaCentre Hospitalier Universitaire de Caen Normandie, Caen, France.
Dina NaguibCentre Hospitalier Universitaire de Caen Normandie, Caen, France.
Guénaelle LevalletCentre Hospitalier Universitaire de Caen Normandie, Caen, France.
Elizabeth BattersbyCentre Hospitalier Universitaire de Caen Normandie, Caen, France.
Sylvain ChantepieCentre Hospitalier Universitaire de Caen Normandie, Institut D'hématologie Bas Normand (IHBN), Caen, France.
Yohann RepesséCentre Hospitalier Universitaire de Caen Normandie, Caen, France.
Coralie NectouxCentre Hospitalier Universitaire de Caen Normandie, Caen, France.
Elsa MaitreCentre Hospitalier Universitaire de Caen Normandie, Caen, France.ORCID https://orcid.org/0000-0002-5967-8225

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionQuantification and monitoring of NPM1 mutations represent a key tool in the management of acute myeloid leukemia (AML), offering strong prognostic value and serving as a marker of minimal residual disease (MRD). Digital PCR (dPCR) provides absolute quantification with high sensitivity and specificity, offering advantages over conventional qPCR-based methods, particularly for rare or atypical NPM1 mutations.

methodsWe adapted and evaluated a digital PCR strategy including both monoplex and multiplex assays targeting the most common NPM1 mutations (types A, B, D) as well as rare variants. A touch-down PCR protocol was optimized to harmonize the dPCR protocol and enhance specificity. Assay performance was evaluated in terms of limit of detection (LoD), limit of quantification (LoQ), linearity, and specificity, and compared to quantitative PCR (qPCR).

resultsThe multiplex dPCR assay allowed detection of all clinically relevant NPM1 mutations with an LoD of 0.01%, while monoplex type A, B and D assays reached 0.001% for type A, B and D. The method showed strong linearity (R

conclusionThe approach enabled early relapse prediction in selected patients and improved molecular follow-up, even for rare NPM1 mutations not covered by standard qPCR panels. It simplifies laboratory routine and improves MRD assessment, according to current ELN guidelines and the growing need for personalized molecular monitoring in AML.

Indexed as

Leukemia, Myeloid, AcuteMutationNuclear ProteinsPolymerase Chain ReactionDNA Mutational AnalysisHumansNeoplasm, ResidualNucleophosminNPM1 protein, humanNuclear ProteinsNucleophosminacute myeloid leukemiadigital PCRminimal residual diseaseNPM1personalized monitoringrare mutations

Identifiers

PMID42298870
PMCPMC13555100

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.